Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Matrixx guidance

This article was originally published in The Tan Sheet

Executive Summary

Matrixx Initiatives cites the introduction of new products along with the "ongoing growth" of the Zicam line in its announcement to increase fiscal year 2005 guidance Dec. 13. The company expects total revenues for 2005 to grow 45%-50% over fiscal 2004 (up from the original 25%-35%), and earnings per share to increase 35%-45% (up from 10%-20%). "This year's positive results include our increased marketing activity to build consumer awareness and trial for the Zicam brand," Matrixx CEO Carl Johnson says. "They also reflect the strong introductory support of the new Nasal Comfort products." The firm reported that retail sales of Zicam products increased 37% for the twelve-week period ended Nov. 27, while the total cough/cold category grew 2% compared to the prior-year period...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS098942

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel